Hims & Hers Health, Inc. (NYSE:HIMS) Given Average Recommendation of "Hold" by Brokerages

Shares of Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) have received an average recommendation of "Hold" from the seventeen brokerages that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $25.13.

A number of analysts have issued reports on the company. Bank of America downgraded Hims & Hers Health from a "buy" rating to an "underperform" rating and decreased their price target for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. TD Cowen restated a "buy" rating and set a $28.00 target price on shares of Hims & Hers Health in a research note on Wednesday, November 20th. BTIG Research assumed coverage on shares of Hims & Hers Health in a research note on Tuesday. They issued a "buy" rating and a $35.00 price target on the stock. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a "hold" rating in a research report on Wednesday, November 6th. Finally, Canaccord Genuity Group lifted their price target on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a "buy" rating in a research note on Monday, December 2nd.

Hims & Hers Health Stock Performance

Shares of HIMS traded down $0.32 during midday trading on Friday, hitting $25.41. The company had a trading volume of 9,224,298 shares, compared to its average volume of 9,547,191. Hims & Hers Health has a 1 year low of $8.14 and a 1 year high of $35.02. The firm has a market capitalization of $5.55 billion, a P/E ratio of 57.75 and a beta of 1.31. The company's 50-day simple moving average is $27.21 and its 200-day simple moving average is $21.65.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. During the same quarter in the previous year, the firm earned ($0.04) earnings per share. The firm's quarterly revenue was up 77.1% on a year-over-year basis. Equities analysts predict that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 2,339 shares of the firm's stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $20.41, for a total value of $47,738.99. Following the completion of the sale, the insider now owns 172,274 shares of the company's stock, valued at approximately $3,516,112.34. This trade represents a 1.34 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Oluyemi Okupe sold 269,739 shares of the stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $20.31, for a total transaction of $5,478,399.09. Following the completion of the transaction, the chief financial officer now owns 145,763 shares of the company's stock, valued at $2,960,446.53. This represents a 64.92 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,333,446 shares of company stock worth $34,175,197 over the last 90 days. 17.71% of the stock is currently owned by insiders.

Institutional Trading of Hims & Hers Health

A number of institutional investors have recently bought and sold shares of the company. Main Management ETF Advisors LLC acquired a new position in shares of Hims & Hers Health during the 3rd quarter worth approximately $672,000. Robeco Institutional Asset Management B.V. acquired a new position in shares of Hims & Hers Health in the third quarter worth $604,000. Carnegie Investment Counsel purchased a new stake in shares of Hims & Hers Health in the third quarter valued at $5,531,000. Royce & Associates LP boosted its stake in shares of Hims & Hers Health by 17.0% during the third quarter. Royce & Associates LP now owns 341,000 shares of the company's stock valued at $6,281,000 after acquiring an additional 49,500 shares during the last quarter. Finally, Versor Investments LP purchased a new stake in Hims & Hers Health during the 3rd quarter worth about $634,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.